By Ted Bosworth
Originally published by our sister publication Clinical Oncology News
The addition of the bispecific T-cell engager blinatumomab (Blincyto, Amgen) to the consolidation regimen of patients with previously untreated B-lineage acute lymphoblastic leukemia (ALL) provides an overall survival benefit whether or not patients achieve negative minimal residual disease (MRD) status after induction treatment, according to interim results of a phase 3 trial.
Blinatumomab has been